YANGZHOU, China, April 14, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, today reported its financial results for the fiscal year ended December 31, 2022. All amounts below are in U.S. dollars.
Fiscal Year 2022 Financial Metrics:
For the Years Ended December 31 | |||||||||||
(in $ millions, except earnings per share; | 2022 | 2021 | % Change | ||||||||
Revenues | $ |
103.3 | $ | 104.0 |
(1 %) | ||||||
Gross profit | 38.1 | 39.8 | (4 %) | ||||||||
Gross margin |
37 % | 38 % | (1 percentage point) | ||||||||
Income from operations | 10.8 | 26.3 | (59 %) | ||||||||
Net income attributable to shareholders | 6.2 | 20.9 | (70 %) | ||||||||
Net income per share – Basic and Diluted | 0.27 | 1.05 | (75 %) | ||||||||
Mr. Yongjun Liu, Chairman of MHUA, commented: "The Company is pleased to announce resilient results for the past fiscal year, despite experiencing some uncertainty in the macro-environment and disturbances in the supply chain and logistics network especially during the fourth quarter. We reported stable revenue of approximately $103.3 million for 2022, compared to approximately $104.0 million in 2021 and maintained our gross margin at 37%. We believe that the Company is now better positioned for the upcoming year as it is fully geared to drive through new initiatives with diversification into high-end product offerings, as well as expansion to untapped global markets. Our strategy in the new fiscal year continues to focus on growing revenues with an emphasis on long-term opportunities across multiple business strings at scale."
Fiscal Year 2022 Financial Results:
Revenues
Revenues decreased by approximately $0.7 million, or approximately 1%, to $103.3 million for the year ended December 31, 2022 from approximately $104.0 million for the year ended December 31, 2021. The slight decrease was mainly due to a decline in demand for customer orders.
Cost of revenues
Cost of revenues primarily include cost of materials, direct labor costs, overhead, and other related incidental expenses that are directly attributable to the Company's principal operations. Cost of revenues increased by approximately $1.0 million, or approximately 2%, to approximately $65.2 million for the year ended December 31, 2022 from approximately $64.2 million for the year ended December 31, 2021. The increase was mainly due to an increase in the price of materials.
Gross profit and margin
Gross profit decreased by approximately $1.7 million, or approximately 4%, to approximately $38.1 million for the year ended December 31, 2022 from $39.8 million for the year ended December 31, 2021. Gross profit margin decreased from 38% for the year ended December 31, 2021 to 37% for the year ended December 31, 2022 due to an increase in the cost of materials.
Operating costs and expenses
Our operating costs and expenses consist of selling expenses, general and administrative expenses and research and development expenses.
- Selling
Selling expenses increased by approximately $0.7 million, or approximately 10%, to approximately $7.1 million for the year ended December 31, 2022 from approximately $6.5 million for the year ended December 31, 2021. The increase was mainly attributable to the combined effects of the following:'
(a) Conference expenses increased by approximately $0.4 million to approximately $1.1 million for the year ended December 31, 2022 from approximately $0.8 million for the year ended December 31, 2021. The conference expense is mainly attributable to expenses related to the Company's market expansion, business development, business negotiation, medical expo, and exhibition affairs. These expenditures helped the Company promote its products, develop markets and channels, strengthen customer communication, and establish long-term and stable cooperative relations;
(b) Transportation expenses decreased by approximately $0.2 million, or approximately 8%, to approximately $2.6 million for the year ended December 31, 2022 from approximately $2.8 million for the year ended December 31, 2021. The decrease was mainly attributable to the reduction in business travel associated with business expansion, which was impacted by COVID-related controls implemented by local governments in fiscal year 2022;
(c) Salaries and benefits expenses increased by approximately $0.2 million or approximately 14%, to approximately $1.5 million for the year ended December 31, 2022 from approximately $1.3 million for the year ended December 31, 2021. The increase was mainly attributable to the fact that the COVID-19 pandemic in China had been brought under control and the local government canceling the social insurance relief policy; and
(d) Entertainment expenses increased by approximately $0.4 million, or approximately 50%, to approximately $1.2 million for the year ended December 31, 2022 from approximately $0.8 million for the year ended December 31, 2021. The increase was mainly attributable to the Company's business expansion and new customer acquisition.
- General and administrative expenses
General and administrative expenses increased by approximately $8.1 million, or approximately 186%, to approximately $12.5 million for the year ended December 31, 2022, from approximately $4.4 million for the year ended December 31, 2021. The increase was primarily due to (a) service expenses increasing by approximately $7.0 million from approximately $0.2 million for the year ended December 31, 2021 to approximately $7.2 million for the year ended December 31, 2022, (b) entertainment expenses increasing by approximately $0.4 million, or 51%, from approximately $0.8 million for the year ended December 31, 2021 to approximately $1.2 million for the year ended December 31, 2022, (c) conference fee expenses increasing by approximately $0.3 million from approximately $0.5 million for the year ended December 31, 2021 to approximately $0.8 million for the year ended December 31, 2022, and (d) salaries and benefits increasing by approximately $0.1 million from approximately $1.2 million for the year ended December 31, 2021 to approximately $1.4 million for the year ended December 31, 2022.
- Research and development expenses
Research and development expenses increased by approximately $0.2 million, or approximately 9%, to approximately $3.0 million for the year ended December 31, 2022, from approximately $2.7 million for the year ended December 31, 2021. The increase was mainly due to the increase in salaries and benefits expenses which was mainly attributable to that the pandemic in China had been brought under control and the local government had canceled the social insurance relief policy.
Income from operations
As a result of the factors described above, our income from operations decreased by approximately $15.5 million, or approximately 59%, to approximately $10.8 million for the year ended December 31, 2022 from approximately $26.3 million for the year ended December 31, 2021.
Net income
Our net income decreased by approximately $14.8 million, or approximately 71%, to approximately $6.2 million for the fiscal year ended December 31, 2022 from approximately $20.9 million for the fiscal year ended December 31, 2021. The decrease was mainly due to a sharp increase in service expenses and writing off the Tai He deposit.
Recent developments
On February 21, 2023, the Company announced that via its subsidiary company Hainan Guoxie Medical Technology Co., it entered into a cooperation agreement with Qionghai City of Hainan Province to build technology park project. Hainan Guoxie also entered into cooperation agreement with Hainan Free Trade Port Boao Hope City to build MHUA a medical research and development center in the Hope City.
On February 15, 2023, the Company announced it has built up a team to lead the research and development of a robotic surgical system and efforts to apply for approval for production launch. The Company plans to engage in the design of a surgical robotic assisted surgery ("RAS") system and the integration of related software and hardware.
On February 08, 2023, the Company announced plan to explore the application of ChatGPT technologies to develop online health consultation services and is now actively laying out the research and development of related facilities application and technology platforms.
On January 11, 2023, the Company announced that its subsidiary Jiangsu Huadong Medical Device Industrial Co., Ltd entered into a strategic cooperation agreement with Getein Biotech Inc. (SHA: 603387) to jointly produce and sell Covid-19 antigen test kits and other in vitro diagnostics (IVD) products.
About Meihua International Medical Technologies Co., Ltd.
Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strip, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under Meihua's own brands and are also sourced and distributed from other manufacturers. The Company has received international "CE" certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for over 30 years, providing over 1,000 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania. For more information, please visit www.meihuamed.com .
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's ability to achieve its goals and strategies, and its ability to fully execute on the planned agreement, the Company's future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, including under the section entitled "Risk Factors" in its annual report on Form 20-F, as filed with the SEC on April 14, 2023, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Janice Wang
Wealth Financial Services LLC
Phone:
+86 13811768599
+1 628 283 9214
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD. | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
As of December 31, 2022 and 2021 | ||||||||
(US$, except share data or otherwise noted) | ||||||||
2022 | 2021 | |||||||
Assets | ||||||||
Current Assets | ||||||||
Cash | $ | 26,736,700 | $ | 8,149,276 | ||||
Bank acceptance receivables | 22,085,846 | 19,379,845 | ||||||
Accounts receivable | 68,945,792 | 67,101,297 | ||||||
Inventories | 1,122,038 | 1,251,393 | ||||||
Prepayment and other current assets | 16,428,779 | 1,394,539 | ||||||
Total current assets | 135,319,155 | 97,276,350 | ||||||
Property, plant and equipment | 8,758,047 | 7,477,744 | ||||||
Intangible assets | 497,600 | 562,001 | ||||||
Investment | 6,669,655 | 941,531 | ||||||
Other noncurrent assets | 12,333,122 | - | ||||||
Deposits | - | 30,599,755 | ||||||
Total assets | $ | 163,577,579 | $ | 136,857,381 | ||||
Liabilities and shareholders' equity | ||||||||
Liabilities | ||||||||
Current liabilities | ||||||||
Short-term bank borrowings | $ | 6,089,428 | $ | 5,178,420 | ||||
Accounts payable | 16,096,165 | 20,981,041 | ||||||
Taxes payable | 1,131,276 | 2,082,252 | ||||||
Accrued expenses and other current liabilities | 856,698 | 847,066 | ||||||
Total current liabilities | 24,173,567 | 29,088,779 | ||||||
Long term loan | 724,932 | - | ||||||
Total liabilities | 24,898,499 | 29,088,779 | ||||||
Commitments and contingencies | ||||||||
Shareholders' equity | ||||||||
Ordinary share, $0.0005 par value, 80,000,000 shares | 11,970 | 10,000 | ||||||
Preferred share, $0.0005 par value, 20,000,000 shares | - | - | ||||||
Additional paid-in capital | 42,967,006 | 9,716,484 | ||||||
Statutory surplus reserves | 15,665,860 | 15,178,467 | ||||||
Retained earnings | 83,330,239 | 77,574,663 | ||||||
Accumulated other comprehensive income (loss) | (3,852,138) | 5,288,988 | ||||||
Total shareholders' equity | 138,122,937 | 107,768,602 | ||||||
Non-controlling interest | 556,143 | - | ||||||
TOTAL EQUITY | 138,679,080 | 107,768,602 | ||||||
Total liabilities and shareholders' equity | $ | 163,577,579 | $ | 136,857,381 | ||||
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD. | ||||||||||||
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME | ||||||||||||
For the years ended December 31, 2022, 2021 and 2020 | ||||||||||||
(US$, except share data or otherwise noted) | ||||||||||||
For the Years Ended December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
Revenues | ||||||||||||
Third party sales | $ | 103,317,145 | $ | 103,461,809 | $ | 88,244,403 | ||||||
Related party sales | 29,196 | 575,901 | 816,607 | |||||||||
Total revenues | 103,346,341 | 104,037,710 | 89,061,010 | |||||||||
Cost of revenues | 65,247,864 | 64,232,469 | 51,900,823 | |||||||||
Gross profit | 38,098,477 | 39,805,241 | 37,160,187 | |||||||||
Operating expenses | ||||||||||||
Selling | 7,109,524 | 6,457,801 | 6,624,332 | |||||||||
General and administrative | 12,468,551 | 4,361,472 | 4,577,570 | |||||||||
Research and development | 2,962,904 | 2,725,014 | 2,492,059 | |||||||||
Written-off of Tai He deposit | 4,755,536 | - | - | |||||||||
Total operating expenses | 27,296,515 | 13,544,287 | 13,693,961 | |||||||||
Income from operations | 10,801,962 | 26,260,954 | 23,466,226 | |||||||||
Other (income) expense: | ||||||||||||
Interest expense | 194,667 | 180,744 | 137,160 | |||||||||
Interest income | (63,725) | (23,855) | (36,583) | |||||||||
Currency exchange gain | (273,432) | (174,413) | (393,478) | |||||||||
Other expense, net | 53,205 | 50,437 | 25,551 | |||||||||
Total other (income) expenses | (89,285) | 32,913 | (267,350) | |||||||||
Income before income tax provision | 10,891,247 | 26,228,041 | 23,733,576 | |||||||||
Income taxes expense | 4,713,543 | 5,278,462 | 4,688,321 | |||||||||
Net income | 6,177,704 | $ | 20,949,579 | $ | 19,045,255 | |||||||
Net loss attributable to non-controlling interests | (65,265) | - | - | |||||||||
Net income attributable to shareholders | 6,242,969 | 20,949,579 | 19,045,255 | |||||||||
Foreign currency translation adjustment – gain / | (9,155,028) | 2,083,243 | 4,759,973 | |||||||||
Comprehensive (loss) income | $ | (2,977,324) | $ | 23,032,822 | $ | 23,805,228 | ||||||
Comprehensive loss attributable to non- | (79,167) | - | - | |||||||||
Comprehensive (loss) income attributable to | (2,898,157) | 23,032,822 | 23,805,228 | |||||||||
Weighted average number of ordinary shares - | 23,411,068 | 20,000,000 | 20,000,000 | |||||||||
Basic & diluted net income per ordinary share | $ | 0.27 | $ | 1.05 | $ | 0.95 | ||||||
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD. | ||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||
For the years ended December 31, 2022, 2021 and 2020 | ||||||||||||
(US$) | ||||||||||||
For the Year Ended December 31 | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
Cash Flows from operating activities: | ||||||||||||
Net income | $ | 6,177,704 | $ | 20,949,579 | $ | 19,045,255 | ||||||
Adjustments for items not affecting cash: | ||||||||||||
Depreciation | 541,265 | 595,522 | 497,238 | |||||||||
Amortization | 22,196 | 26,951 | 26,195 | |||||||||
Net loss from disposal of property, plant and | 25,023 | 15,281 | 2,852 | |||||||||
Change in bad debt allowance | 4,755,536 | - | - | |||||||||
Currency exchange (gain) loss | (273,432) | - | - | |||||||||
Changes in operating assets and liabilities: | - | |||||||||||
Bank acceptance receivables | (4,284,515) | (6,533,717) | (5,764,940) | |||||||||
Accounts receivable | (7,121,889) | (20,065,904) | (13,644,830) | |||||||||
Inventories | 35,027 | 105,121 | (219,787) | |||||||||
Prepayments and other assets | (4,932,145) | (861,799) | (367,249) | |||||||||
Due from related parties | - | 396,583 | (222,504) | |||||||||
Accounts payable | (3,371,275) | 4,908,971 | 5,341,710 | |||||||||
Taxes payable | (812,412) | 288,659 | 598,105 | |||||||||
Accrued expenses and other current liabilities | 75,879 | 120,090 | 102,749 | |||||||||
Due to related parties | - | - | (68,798) | |||||||||
Net cash (used in) provided by operating activities | (9,163,038) | (54,663) | 5,325,996 | |||||||||
Cash flows from investing activities: | ||||||||||||
Purchases of property, plant and equipment | (2,698,729) | (850,231) | (3,808,259) | |||||||||
Payments for long-term deposits for buildings | - | - | (12,311,347) | |||||||||
Long term investment | (5,944,709) | - | - | |||||||||
Proceeds from disposal of property, plant and | 23,146 | 16,414 | 25,202 | |||||||||
Net cash used in investing activities | (8,620,292) | (833,817) | (16,094,404) | |||||||||
Cash flows from financing activities: | ||||||||||||
Proceeds from short-term bank borrowings | 7,579,135 | 6,510,820 | 4,359,665 | |||||||||
Proceeds from long-term bank loans | 743,052 | - | - | |||||||||
Capital contributed by non-controlling shareholders | 635,310 | - | - | |||||||||
Proceeds from initial public offering | 34,529,644 | - | - | |||||||||
Proceeds from issuance of shares | - | 1,272,232 | ||||||||||
Repayments of short-term bank borrowings | (6,241,641) | (4,650,586) | (3,925,147) | |||||||||
Net cash provided by financing activities | 37,245,500 | 1,860,234 | 1,706,750 | |||||||||
Effect of foreign exchange rate changes | (874,746) | (9,812) | 218,137 | |||||||||
Net increase (decrease) in cash | 18,587,424 | 961,942 | (8,843,521) | |||||||||
Cash, beginning of year | 8,149,276 | 7,187,334 | 16,030,855 | |||||||||
Cash, end of year | $ | 26,736,700 | $ | 8,149,276 | $ | 7,187,334 | ||||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS | ||||||||||||
Cash paid during the period for: | ||||||||||||
Interest | $ | 194,667 | $ | 180,744 | $ | 137,160 | ||||||
Income taxes | $ | 5,703,288 | $ | 5,042,816 | $ | 4,362,169 | ||||||
Non cash provided (used) in financing activities | ||||||||||||
Shareholder contribution through deferred cost | 1,277,152 | |||||||||||
| Last Trade: | US$0.31 |
| Daily Change: | 0.002 0.65 |
| Daily Volume: | 545,047 |
| Market Cap: | US$8.090M |
August 26, 2024 July 31, 2024 May 07, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
